Cognitive Conditioned Pain Modulation (CognitiveCPM)

January 2, 2026 updated by: Hunter Hoffman, University of Washington

Conditioned Pain Modulation With Ultra-Brief Conditioning Stimulus

This "pain reduces pain" study looks at how the brain reduces pain when a person feels two painful sensations at the same time. There is considerable evidence that the brain can "turn down" pain using natural endogenous pain-control systems. The current CPM study measures whether attentional processes can also make a measurable contribution to pain inhibition alongside neurochemical mechanisms.

Study Overview

Detailed Description

Conditioned pain modulation (CPM) is a natural process where feeling pain in one part of the body (e.g., a conditioning stimulus to the wrist) can reduce pain felt in another part of the body (a test stimulus to the foot). There is considerable evidence from both animal and human studies that the painful conditioning stimulus can stimulate the brain to activate neurochemical pain-control pathways (e.g., endogenous opioids), which are believed to take 30-120 seconds to fully engage. The current CPM study measures whether attentional processes can also make a measurable contribution to pain inhibition alongside neurochemical mechanisms.

Primary measures: Graphic ratings scale "worst pain" ratings.

The primary measure of the current study graphic ratings scales (worst pain ratings) will measure how much pain participants feel on their foot during foot only (test stimulus), vs. how much pain participants feel on their foot (test stimulus during simultaneous foot (test stimulus) + wrist (conditioning stimulus).

The current investigators predict that pain (e.g., the conditioning stimulus) naturally demands attention and can pull attention away from the original pain source (the test stimulus), resulting in CPM-like reductions in pain of the test stimulus.

Secondary measure #1. Cognitive measures are introduced in the current study, to quantify how much (if at all) the conditioning stimulus reduces pain of the target stimulus via attentional mechanisms. Participants estimate what percentage of their attention was directed to their foot (the test stimulus) during foot only vs. during foot + wrist (test + conditioning stimulus). This will measure whether the conditiioning stimulus to the wrist reduces how much attention participants focus on their foot. Analyses will also measure whether the amount of attention shift away from the foot (via participants; subjective ratings) is correlated with CPM robustness (reduction in pain of foot during duel stimulation).

Secondary measure #2. As another secondary measure of attention during one vs. two simultaneous pain stimuli, this study involves a divided attention auditory listening task that becomes harder when pain demands more attention (Craik et al., odd number divided attention task during single test pain stimuli vs. simultaneous test + conditioning stimuli). The more errors the participant makes on the divided attention task, the more attention diverted away from the auditory task by pain. Analyses will measure whether the number of errors on the divided attention task is correlated with CPM robustness (reduction in pain of foot, during duel thermal stimulation).

Exploratory measures. As exploratory measures, participants will rate how distracted they were and how difficult it was to concentrate (on 0-10 rating scales during test stimulus alone verses test + conditioning noxious thermal heat stimuli).

In summary, embedding these cognitive measures into the CPM protocol may enhance mechanistic interpretation accuracy by quantifying attentional contributions to pain inhibition in specific CPM protocols, thereby complementing existing approaches to pain phenotyping and reducing unexplained variance in CPM outcomes.

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Washington
      • Seattle, Washington, United States, 98195
        • University of Washington Seattle

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion criteria:

  • Only University of Washington students in eligible psychological courses are
  • eligible. General public is not eligible.
  • Enrolled psychology students fluent in English,
  • Age ≥18 y, able to follow instructions.

Exclusion criteria:

  • Seizure history,
  • Migraines,
  • Diabetes,
  • Extreme pain insensitivity,
  • Motion sickness,
  • or prior participation in this protocol.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Single pain stimulus
test pain stimulus alone
single brief stimulus to foot only
Experimental: dual pain stimuli
simultaneous foot (test stimulus + wrist (conditioning stimulus)
simultaneous stimuli to foot (test stimulus) and wrist (conditioning stimulus)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
worst pain ratings of foot only
Time Frame: rated immediately after each thermal stimulus
graphic rating scale from 0 (no pain) to 10 (excruciating pain)
rated immediately after each thermal stimulus
worst pain on graphic rating scale during test+conditioning stimulus
Time Frame: measured immediately after the stimuli
graphic rating scale from 0 (no pain) to 10 (excruciating pain)
measured immediately after the stimuli

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
% of attention devoted to foot during test stimulus only (0-100% scale)
Time Frame: rated immediately after the stimuli
verbal ratings where higher numbers = more attention
rated immediately after the stimuli
% of attention devoted to foot during test+conditioning stimuli (0-100% scale)
Time Frame: rated immediately after the thermal stimuli
verbal ratings where higher numbers = more attention
rated immediately after the thermal stimuli
Divided attention during test stimulus only (% correct, where 100% is highest accuracy)
Time Frame: Day 1, during the thermal stimulus
Accuracy monitoring a string of auditory numbers, the odd number task during test stimulus
Day 1, during the thermal stimulus
Divided attention during test stimulus + conditioning stimulus (% correct, 100% is highest )
Time Frame: Day 1, during the thermal stimuli
Accuracy monitoring a string of auditory numbers, the odd number task during dual stimuli
Day 1, during the thermal stimuli

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
distraction difficulty during test stimulus only (0 to 10 scale, where 10 is most distracting)
Time Frame: immediately after the phase 1 thermal stimuli
Exploratory: Distraction during the single test stimulus (graphic rating scales)
immediately after the phase 1 thermal stimuli
distraction difficult during simultaneous test + conditioning stimuli (graphic rating scale)
Time Frame: Exploratory: immediately after the phase 1 thermal stimuli
Exploratory: 0-10 distraction during simultaneous test + conditioning stimulus (10 =highest distraction)
Exploratory: immediately after the phase 1 thermal stimuli
difficulty concentrating during test stimulus only (0 to 10 scale, 10 = most difficult concentr
Time Frame: Exploratory: immediately after the phase 1 thermal stimuli
Exploratory: difficulty concentrating during the single test stimulus (graphic scales)
Exploratory: immediately after the phase 1 thermal stimuli
difficulty concentrating during simultaneous test + conditioning stimuli (graphic rating scale)
Time Frame: Exploratory: immediately after the phase 1 thermal stimuli
Exploratory: difficulty concentrating during simultaneous test + conditioning stimulus, 10 = most difficult
Exploratory: immediately after the phase 1 thermal stimuli

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Hunter Hoffman, University of Washington

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 9, 2024

Primary Completion (Actual)

May 29, 2025

Study Completion (Actual)

May 29, 2025

Study Registration Dates

First Submitted

November 14, 2025

First Submitted That Met QC Criteria

November 14, 2025

First Posted (Estimated)

November 18, 2025

Study Record Updates

Last Update Posted (Actual)

January 7, 2026

Last Update Submitted That Met QC Criteria

January 2, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CPM2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Summary statistics will be made available to researchers upon reasonable request (e.g, for meta-analyses, etc). No individually identifiable information will be made available.

IPD Sharing Time Frame

The de-identified summary data will be available from time of publication for at least five years after publication.

IPD Sharing Access Criteria

The de-identified summary data will be e-mailed to researchers upon reasonable request

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Participants

Clinical Trials on test stimulus

Subscribe